Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Dec;3(12):50-9.

Time to response in generalized anxiety disorder in a naturalistic setting: combination therapy with alprazolam orally disintegrating tablets and serotonin reuptake inhibitors compared to serotonin reuptake inhibitors alone

Mark Hyman Rapaport  1 , Steve B Skarky, David J Katzelnick, Jeffrey N Dewester, James M Harper, Kay E McCrary
Affiliations

Time to response in generalized anxiety disorder in a naturalistic setting: combination therapy with alprazolam orally disintegrating tablets and serotonin reuptake inhibitors compared to serotonin reuptake inhibitors alone

Mark Hyman Rapaport et al. Psychiatry (Edgmont). 2006 Dec.

Abstract

Objective: This study investigated the therapeutic potential of initiating treatment of generalized anxiety disorder (GAD) with alprazolam orally disintegrating tablets (ODT) in combination with an SSRI or SNRI, compared with SSRI/SNRI monotherapy.

Design: Subjects were randomized to eight weeks open-label treatment with alprazolam ODT (4 weeks treatment followed by a 3- to 4-week taper) combined with an SSRI or SNRI, or treatment with SSRI/SNRI alone.

Setting: The study was conducted at 43 primary care and 22 psychiatric practices under naturalistic conditions.

Participants: Subjects ≥ 18 years of age with a primary diagnosis of GAD.

Measurements: The primary efficacy measure was time to response, a ≥50-percent decrease from baseline in Hamilton Rating Scale for Anxiety (HAM-A) total score. Secondary variables included HAM-A total and sub-factor scores, and the Clinical Global Impression of Improvement (CGI-I) and Patient Global Impression (PGI) scales.

Results: The intent-to-treat population included 129 subjects. Discontinuation due to adverse events occurred in one subject in each group. There was no statistical difference between groups in the primary efficacy variable of time to response on the HAM-A. Combination treatment with alprazolam ODT and SSRI/SNRI was associated with statistically significant advantages on prespecified secondary variables including earlier improvement in the HAM-A total score and insomnia item and responses on the CGI-I and PGI scales.

Conclusion: Combination treatment did not differ from monotherapy on time to response but was associated with more rapid improvement in insomnia and global secondary measures.

Keywords: SNRI; SSRI; alprazolam; generalized anxiety disorder; naturalistic.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier estimate of time to response in the ITT population
Figure 2
Figure 2
Proportion of subjects rated “Very Much Improved” or “Much Improved” on the physician-rated Clinical Global Impression of Improvement scale
Figure 3
Figure 3
Proportion of subjects rated “Very Much Improved” or “Much Improved” on the subject-rated Patient Global Impression scale
Figure 4
Figure 4
Mean change from baseline in HAM-A total scores
Figure 5
Figure 5
Mean change from baseline in HAM-A insomnia item scores
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revision. DSM-IV-R. Washington, DC: American Psychiatric Press, Inc.; 2000.
    1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8–19. - PubMed
    1. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593–602. - PubMed
    1. Carter RM, Wittchen HU, Pfister H, Kessler RC. One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depress Anxiety. 2001;13:78–88. - PubMed
    1. Wittchen HU. Generalized anxiety disorder: Prevalence, burden, and cost to society. Depress Anxiety. 2002;16:162–71. - PubMed

LinkOut - more resources